All Aboriginal and Torres Strait Islander people aged 2 months to 19 years are recommended to receive MenB vaccine

Aboriginal and Torres Strait Islander people aged 2 months to 19 years are recommended to receive a course of MenB vaccine.

MenB vaccine is funded through the NIP for all Aboriginal and Torres Strait Islander people aged ≥2 months - <2 years. For details see the National Immunisation Program Schedule.

The dose schedule for MenB vaccine depends on the brand and the person’s age when they start the vaccine course.

For infants commencing vaccination at 2 months of age, MenB vaccine is recommended in a 3-dose schedule at 2, 4 and 12 months of age.

Aboriginal and Torres Strait Islander infants and children with specified medical risk conditions are recommended to receive an additional dose of MenB vaccine at 6 months of age, see People with medical conditions that increase their risk of invasive meningococcal disease.

Infants can have their 1st dose of MenB vaccine as early as 6 weeks of age. If the 1st dose of MenB vaccine is given at the age of 6 weeks, infants should still receive their next scheduled doses at 4 months and 12 months of age.

For children aged <2 years who did not commence vaccination at 2 months of age, see Infants and children aged <2 years are recommended to receive MenB vaccine.

People aged 2–9 years should receive 2 doses of MenB vaccine, 8 weeks apart.

People aged ≥10 years can receive 2 doses of either brand of MenB vaccine:

• 2 doses of Bexsero, with 8 weeks between doses, or
• 2 doses of Trumenba, with 6 months between doses

There is no preference for either brand of MenB vaccine - Bexsero or Trumenba - for people aged ≥10 years.

Bexsero and Trumenba are not interchangeable. The same vaccine should be used for both vaccine doses.